Cargando…

Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma

BACKGROUND: Bendamustine is an attractive option for the management of both de novo and relapsed lymphomas. It is being increasingly used in the conditioning regimen for autologous stem cell transplantation (SCT) and can be an alternative to the traditionally-used carmustine. In this study, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Shabbir-Moosajee, Munira, Jehangir, Samad, Sawani, Sobiya, Muhammed, Tariq, Ali, Natasha, Sheikh, Usman, Adil, Salman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614092/
https://www.ncbi.nlm.nih.gov/pubmed/31309088
http://dx.doi.org/10.5045/br.2019.54.2.108
_version_ 1783433121082900480
author Shabbir-Moosajee, Munira
Jehangir, Samad
Sawani, Sobiya
Muhammed, Tariq
Ali, Natasha
Sheikh, Usman
Adil, Salman
author_facet Shabbir-Moosajee, Munira
Jehangir, Samad
Sawani, Sobiya
Muhammed, Tariq
Ali, Natasha
Sheikh, Usman
Adil, Salman
author_sort Shabbir-Moosajee, Munira
collection PubMed
description BACKGROUND: Bendamustine is an attractive option for the management of both de novo and relapsed lymphomas. It is being increasingly used in the conditioning regimen for autologous stem cell transplantation (SCT) and can be an alternative to the traditionally-used carmustine. In this study, we aimed to determine the safety and efficacy of bendamustine in the conditioning regimen for autologous SCT in refractory/relapsed lymphomas. METHODS: We designed a descriptive study to evaluate bendamustine in combination with etoposide, cytarabine, and melphalan (BeEAM) in the conditioning regimen for autologous SCT. RESULTS: Fourteen patients (median age, 28 yr) with Hodgkin's lymphoma (HL) (N=8), non-Hodgkin's lymphomas (NHL) (N=5), or peripheral T-cell lymphoma, not otherwise specified (PTCL NOS) (N=1) were included in the study. A median number of 5.95×10(6) CD34+ cells/kg were transfused. Median times to absolute neutrophil count and platelet engraftment were 17 days and 24 days, respectively. The 100-day transplantation mortality rate was 28% (4 patients). Eight patients (57.14%) had GII-III acute kidney injury, four patients (28.5%) had GIII-IV hyperbilirubinemia, and twelve patients (85%) had GII-III diarrhea. After 3 months, 37% (5 patients) and 21.4% (3 patients) demonstrated complete response and partial response, respectively. The median follow-up was 5.5 months (15 days–19 mo). At the final follow-up, 7 patients (50%) were alive and in CR. CONCLUSION: Our study showed that bendamustine is a potentially toxic agent in the conditioning regimen for autologous SCT, resulting in significant liver, kidney, and gastrointestinal toxicity. Further studies are required to assess its safety and efficacy at reduced doses.
format Online
Article
Text
id pubmed-6614092
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
record_format MEDLINE/PubMed
spelling pubmed-66140922019-07-15 Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma Shabbir-Moosajee, Munira Jehangir, Samad Sawani, Sobiya Muhammed, Tariq Ali, Natasha Sheikh, Usman Adil, Salman Blood Res Original Article BACKGROUND: Bendamustine is an attractive option for the management of both de novo and relapsed lymphomas. It is being increasingly used in the conditioning regimen for autologous stem cell transplantation (SCT) and can be an alternative to the traditionally-used carmustine. In this study, we aimed to determine the safety and efficacy of bendamustine in the conditioning regimen for autologous SCT in refractory/relapsed lymphomas. METHODS: We designed a descriptive study to evaluate bendamustine in combination with etoposide, cytarabine, and melphalan (BeEAM) in the conditioning regimen for autologous SCT. RESULTS: Fourteen patients (median age, 28 yr) with Hodgkin's lymphoma (HL) (N=8), non-Hodgkin's lymphomas (NHL) (N=5), or peripheral T-cell lymphoma, not otherwise specified (PTCL NOS) (N=1) were included in the study. A median number of 5.95×10(6) CD34+ cells/kg were transfused. Median times to absolute neutrophil count and platelet engraftment were 17 days and 24 days, respectively. The 100-day transplantation mortality rate was 28% (4 patients). Eight patients (57.14%) had GII-III acute kidney injury, four patients (28.5%) had GIII-IV hyperbilirubinemia, and twelve patients (85%) had GII-III diarrhea. After 3 months, 37% (5 patients) and 21.4% (3 patients) demonstrated complete response and partial response, respectively. The median follow-up was 5.5 months (15 days–19 mo). At the final follow-up, 7 patients (50%) were alive and in CR. CONCLUSION: Our study showed that bendamustine is a potentially toxic agent in the conditioning regimen for autologous SCT, resulting in significant liver, kidney, and gastrointestinal toxicity. Further studies are required to assess its safety and efficacy at reduced doses. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2019-06 2019-06-25 /pmc/articles/PMC6614092/ /pubmed/31309088 http://dx.doi.org/10.5045/br.2019.54.2.108 Text en © 2019 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Shabbir-Moosajee, Munira
Jehangir, Samad
Sawani, Sobiya
Muhammed, Tariq
Ali, Natasha
Sheikh, Usman
Adil, Salman
Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma
title Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma
title_full Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma
title_fullStr Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma
title_full_unstemmed Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma
title_short Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma
title_sort safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614092/
https://www.ncbi.nlm.nih.gov/pubmed/31309088
http://dx.doi.org/10.5045/br.2019.54.2.108
work_keys_str_mv AT shabbirmoosajeemunira safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma
AT jehangirsamad safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma
AT sawanisobiya safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma
AT muhammedtariq safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma
AT alinatasha safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma
AT sheikhusman safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma
AT adilsalman safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma